Small cell lung cancer transformation and T790M mutation: Complimentary roles in acquired resistance to kinase inhibitors in lung cancer

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Suda, Kenichi ^a,b   Murakami, Isao ^c   Sakai, Kazuko ^a   Mizuuchi, Hiroshi ^a   Shimizu, Shigeki ^d   Sato, Katsuaki ^a   Tomizawa, Kenji ^a   Tomida, Shuta ^a   Yatabe, Yasushi ^e   Nishio, Kazuto ^a   Mitsudomi, Tetsuya ^a  

^a KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c National Hospital Organization Higashihiroshima Medical Center   (Japan)

^d HYOGO COLLEGE OF MEDICINE   (Japan)

^e AICHI CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CODON; EPIDERMAL GROWTH FACTOR RECEPTOR; PROTEIN KINASE INHIBITOR; SCATTER FACTOR RECEPTOR;

AGED; AMINO ACID SUBSTITUTION; CANCER STAGING; CELL TRANSFORMATION; CODON; COPY NUMBER VARIATION; DRUG RESISTANCE; FEMALE; GENETICS; HUMAN; LUNG NEOPLASMS; METASTASIS; MUTATION; PATHOLOGY; SMALL CELL LUNG CARCINOMA;

AGED; AMINO ACID SUBSTITUTION; ANTINEOPLASTIC AGENTS; CELL TRANSFORMATION, NEOPLASTIC; CODON; DNA COPY NUMBER VARIATIONS; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LUNG NEOPLASMS; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-MET; RECEPTOR, EPIDERMAL GROWTH FACTOR; SMALL CELL LUNG CARCINOMA;

EID: 84942155005     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep14447     Document Type: Article

References (27)

1. Suda, K., Tomizawa, K. & Mitsudomi, T. Biological and clinical significance of KRAS mutations in lung cancer: An oncogenic driver that contrasts with EGFR mutation. Cancer Metast. Rev. 29, 49-60 (2010).
2. Suda, K. & Mitsudomi, T. Successes and limitations of targeted cancer therapy in lung cancer. Progress in Tumor Research 41, 62-77 (2014).
3. Sequist, L. V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).
4. Suda, K., Mizuuchi, H., Maehara, Y. & Mitsudomi, T. Acquired resistance mechanisms to tyrosine kinase inhibitors in lung cancer with activating epidermal growth factor receptor mutation-diversity, ductility, and destiny. Cancer Metast. Rev. 31, 807-14 (2012).
5. Sequist, L. V. et al. Rociletinib in EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med. 372, 1700-9 (2015).
6. Zakowski, M. F., Ladanyi, M. & Kris, M. G. EGFR mutations in small-cell lung cancers in patients who have never smoked. N. Eng. J. Med. 355, 213-5 (2006).
7. Morinaga, R. et al. Sequential occurrence of non-small cell and small cell lung cancer with the same EGFR mutation. Lung Cancer 58, 411-3 (2007).
8. Tatematsu, A. et al. Epidermal growth factor receptor mutations in small cell lung cancer. Clin. Cancer Res. 14, 6092-6 (2008).
9. Fallet, V. et al. Secondary resistance to erlotinib: Acquired T790M mutation and small-cell lung cancer transformation in the same patient. J. Thorac. Oncol. 7, 1061-3 (2012).
10. Watanabe, S. et al. Transformation to small-cell lung cancer following treatment with EGFR tyrosine kinase inhibitors in a patient with lung adenocarcinoma. Lung Cancer 82, 370-2 (2013).
11. Yu, H. A. et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFRmutant lung cancers. Clin. Cancer Res. 19, 2240-7 (2013).
12. Popat, S. et al. Transformation to "high grade" neuroendocrine carcinoma as an acquired drug resistance mechanism in EGFRmutant lung adenocarcinoma. Lung Cancer 80, 1-4 (2013).
13. Kuiper, J. L. et al. Incidence of T790M mutation in (sequential) rebiopsies in EGFR-mutated NSCLC-patients. Lung Cancer 85, 19-24 (2014).
14. Varghese, A. M. et al. Small-cell lung cancers in patients who never smoked cigarettes. J. Thorac. Oncol. 9, 892-6 (2014).
15. Niederst, M. J. et al. RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer. Nat. Commun. 6, 6377 (2015).
16. Jackman, D. et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J. Clin. Oncol. 28, 357-60 (2010).
17. Suda, K. & Mitsudomi, T. Syntax of referencing in PTEN structure, mechanisms-of-Action, role in cell signaling and regulation (ed. Ke Xu.) 101-18 (Nova Science Publishers, 2013).
18. Kohno, T., Takahashi, M., Manda, R. & Yokota, J. Inactivation of the PTEN/MMAC1/TEP1 gene in human lung cancers. Genes Chromosomes Cancer 22, 152-6 (1998).
19. Yokomizo, A. et al. PTEN/MMAC1 mutations identified in small cell, but not in non-small cell lung cancers. Oncogene 17, 475-9 (1998).
20. Forgacs, E. et al. Mutation analysis of the PTEN/MMAC1 gene in lung cancer. Oncogene 17, 1557-65 (1998).
21. Samuels, Y. et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 304, 554 (2004).
22. Suda, K. et al. Reciprocal and complementary role of MET amplification and EGFR T790M mutation in acquired resistance to kinase inhibitors in lung cancer. Clin. Cancer Res. 16, 5489-98 (2010).
23. Scher, K. S., Saldivar, J. S., Fishbein, M., Marchevsky, A. & Reckamp, K. L. EGFR-mutated lung cancer with T790M-Acquired resistance in the brain and histologic transformation in the lung. J. Natl. Compr. Canc. Netw. 11, 1040-4 (2013).
24. Piotrowska, Z. et al. Heterogeneity Underlies the Emergence of EGFR T790 Wild-Type Clones Following Treatment of T790MPositive Cancers with a Third Generation EGFR Inhibitor. Cancer Discov. in press (2015).
25. Takano, T. et al. EGFR mutations predict survival benefit from gefitinib in patients with advanced lung adenocarcinoma: A historical comparison of patients treated before and after gefitinib approval in Japan. J. Clin. Oncol. 26, 5589-95 (2008).
26. Suda, K. et al. CRKL amplification is rare as a mechanism for acquired resistance to kinase inhibitors in lung cancers with epidermal growth factor receptor mutation. Lung Cancer 85, 147-51 (2014).
27. Sakai, K. et al. Chemoradiation provides a physiological selective pressure that increases the expansion of aberrant TP53 tumor variants in residual rectal cancerous regions. Oncotarget 5, 9641-9 (2014).